Clinical Trial Update: Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating retreatment with Velcade (bortezomib) in multiple myeloma patients to assess efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Multiple Myeloma | Phase 4 | Status: COMPLETED